NasdaqGM:VCELBiotechs
Vericel (VCEL): Evaluating Valuation After MACI Revenue Surge and New Growth Initiatives
Vericel (VCEL) attracted fresh attention after reporting a sharp jump in third-quarter earnings and MACI product revenue. This highlights the company’s ability to capitalize on new clinical indications such as MACI Arthro.
See our latest analysis for Vericel.
Vericel’s strong third-quarter drove a sharp recovery in momentum, with a 22% share price return over the past month as investors responded to record MACI revenue, new clinical progress, and international expansion plans. While the stock...